Giardia lamblia: A new target for miltefosine

International Journal for Parasitology

Volumn 42, Issue 5, 2012, Pages 443-452

  Eissa, Maha M ^a   Amer, Eglal I ^a  

^a ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Adherance assay; Electron microscopy; Giardia lamblia; Histopathology; In vitro; In vivo; Miltefosine

Indexed keywords

METRONIDAZOLE; MILTEFORAN; MILTEFOSINE; UNCLASSIFIED DRUG;

BIOASSAY; CONCENTRATION (COMPOSITION); DISEASE TREATMENT; DRUG DEVELOPMENT; HISTOPATHOLOGY; PARASITIC DISEASE; PROTOZOAN; TRANSMISSION ELECTRON MICROSCOPY;

ADHESIVE DISC; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROTOZOAL ACTIVITY; ARTICLE; CELL ADHESION; CELL COMPONENT; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOLYSIS; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; GIARDIA LAMBLIA; GIARDIASIS; GROWTH INHIBITION; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MALE; MEMBRANE DAMAGE; MEMBRANE STRUCTURE; MOUSE; NONHUMAN; PARASITE CLEARANCE; PARASITE CONTROL; SCANNING ELECTRON MICROSCOPY; SINGLE DRUG DOSE; TRANSMISSION ELECTRON MICROSCOPY;

ADMINISTRATION, ORAL; ANIMALS; ANTIPROTOZOAL AGENTS; FEMALE; GIARDIA LAMBLIA; GIARDIASIS; INTESTINES; MALE; MICE; MICROSCOPY, ELECTRON; PARASITIC SENSITIVITY TESTS; PHOSPHORYLCHOLINE; TREATMENT OUTCOME;

GIARDIA INTESTINALIS; MUS;

EID: 84861233179     PISSN: 00207519     EISSN: 18790135     Source Type: Journal    
DOI: 10.1016/j.ijpara.2012.02.015     Document Type: Article

References (49)

1. Adagu S., Nolder D., Warhurst D.C., Rossignol J.F. In vitro activity of nitazxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica and Trichomonas vaginalis. J. Antimicrob. Chemother. 2002, 49:103-111.
2. Adam R. Biology of Giardia lamblia. Clin. Microbiol. Rev. 2001, 14:447-475.
3. Bartke N., Hannun Y.A. Bioactive sphingolipids: metabolism and function. J. Lipid Res. 2009, 50:91-96.
4. Blaha C., Duchêne M., Aspöck H., Walochnik J. In vitro activity of hexadecylphosphocholine (miltefosine) against metronidazole-resistant and-susceptible strains of Trichomonas vaginalis. J. Antimicrob. Chemother. 2006, 57:273-278.
5. Brasseur P., Favennec L. Two cases of giardiasis unsuccessfully treated by albendazole. Parasite. 1995, 2:422.
6. Buraud M., Forget E., Favennec L., Bizet J., Gobert J.G., Deluol A.M. Sexual stage development of cryptosporidia in the Caco-2 cell line. Infect. Immun. 1991, 59:4610-4613.
7. Cedillo R., Enciso J., Mart́i{dotless}nez A., Ortega G. Isolation and axenization of Giardia lamblia isolates from symptomatic and asymptomatic patients in Mexico. Arch. Invest. Med. 1991, 22:79-85.
8. Chose O., Sarde C.O., Noel C., Gerbod D., Jimenez J.C., Brenner C., Capron M., Viscogliosi E., Roseto A. Cell death in protists without mitochondria. Ann. N. Y. Acad. Sci. 2003, 1010:121-125.
9. Croft S.L., Snowdon D., Yardley V. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J. Antimicrob. Chemother. 1996, 38:1041-1047.
10. D́avila C., V́asquez C., Trujillo B., Huerta M. Nitazoxanide compared with quinfamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children. Am. J. Trop. Med. Hyg. 2002, 66:251-254.
11. Drury R.A.B., Wallington E.A. Carleton Histological Technique 1980, Oxford University Press, Oxford, New York, Toronto. fifth ed.
12. Eibl H., Unger C. Hexadecylphosphocholine: a new and selective antitumor drug. Cancer Treat. Rev. 1990, 17:233-242.
13. Eissa M.M., EL-Azzouni M.Z., Amer E.I., Baddour N.M. Miltefosine, a promising novel agent for Schistosomiasis mansoni. Int. J. Parasitol. 2011, 41:235-242.
14. Eissa M.M., El Bardicy S., Tadros M. Bioactivity of miltefosine against aquatic stages of Schistosoma mansoni, Schistosoma haematobium and their snail hosts, supported by scanning electron microscopy. Parasites Vect. 2011, 4:73.
15. Ellis J.E., Wingfield J.M., Cole D., Boreham P.F., Lloyd D. Oxygen affinities of metronidazole-resistant and -sensitive stocks of Giardia intestinalis. Int. J. Parasitol. 1993, 23:35-39.
16. Farthing M.J.G. The molecular pathogenesis of giardiasis. J. Pediatr. Gastroenterol. Nutr. 1997, 24:79-88.
17. Filho A.V.D., Lucas I.C., Sampaio R.N.R. Estudo comparative entre miltefosina oral e antimoniato de N-metil glucamina parenteral no tratamento da leishmaniose experimental causada por Leishmania (Leishmania) amazonensis. Rev. Soc. Bras. Med. Trop. 2008, 41:424-427.
18. Garcia L.S., Bruckner D.A. Macroscopic and microscopic examination of fecal specimens. Diagnostic Medical Parasitology 1997, 608-649. ASM Press, Washington, DC. third ed. L.S. Garcia, D.A. Bruckner (Eds.).
19. Ganguly, N.K., 2002. Oral miltefosine may revolutionize treatment of visceral leishmaniasis. T.D.R. News. WHO, 68, 2.
20. Goppelt-Struebe M., Winter I. Effect of hexadecylphosphocholine on fatty acid metabolism: relation to cytotoxicity. Cancer. Chemother. Pharmacol. 1995, 35:519-526.
21. Hayat M.A. Principles and Techniques of Electron Microscopy: Biological Applications 2000, VNR Company, New York, USA.
22. Kaufmann-Kolle P., Fleer E.A. Morphological changes of adherent and nonadherent cells by treatment with hexadecylphosphocholine and 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine observed by scanning electron microscopy. Prog. Exp. Tumor Res. 1992, 34:47-58.
23. Keister D.B. Axenic culture of Giadia lamblia in TYI-S-33 medium supplemented with bile. Trans. R. Soc. Trop. Med. Hyg. 1983, 77:487-488.
24. Khademi R.F., Ghaffarifar H., Dalimi A.S.L. In vitro effect of folic acid and cobalamin (vitamin B12) on adhesion and growth of Giardia lamblia. Iranian J. Parasitol. 2006, 1:47-52.
25. Kulda J., Nohyhova E. Giardia in humans and animals. Parasitic Protozoa 1995, 229-268. Academic Press. J.P. Kreie (Ed.).
26. Kuhlencord A., Maniera T., Eibi H., et al. Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob. Agents Chemother. 1992, 36:1630-1634.
27. Lahiri S., Futerman A.H. The metabolism and function of sphingolipids and glycosphingolipids. Cell. Mol. Life Sci. 2007, 64:2270-2284.
28. Leméea V., Zahariaa I., Nevezb G., Rabodonirinac M., Brasseura P., Balletd J.J., Favenneca L. Metronidazole and albendazole susceptibility of 11 clinical isolates of Giardia duodenalis from France. J. Antimicrob. Chemother. 2000, 46:819-821.
29. Llull D., Rivas L., Garcia E. In vitro bactericidal activity of the antiprotozoal drug miltefosine against Streptococcus pneumoniae and other pathogenic Streptococci. Antimicrob. Agents Chemother. 2007, 51:1844-1848.
30. Lux H., Hart D.T., Parker P.J., Klenner T. Ether lipid metabolism, GPI anchor biosynthesis, and signal transduction are putative targets for antileishmanial alkyl phospholipids analogues. Adv. Exp. Med. Biol. 1996, 416:201-211.
31. Morrone F., Carneiro J., Reis C., Cardozo C., Ubal C., De Carli G. Study of enteroparasites infection frequency and chemotherapeutic agents used in pediatric patients in a community living in Porto Alegre, RS, Brazil. Rev. Inst. Med. Trop. S̃ao Paulo 2004, 46:77-80.
32. Petri W. Therapy of intestinal protozoa. Trends Parasitol. 2003, 19:523-526.
33. Polat Z.A., Obwaller A., Vural A., Walochnik J. Efficacy of miltefosine for topical treatment of Acanthamoeba keratitis in Syrian hamsters. Parasitol. Res. 2011, 21748351.
34. Rakotomanga M., Loiseau P.M., Saint-Pierre-Chazalet M. Hexadecylphosphocholine interaction with lipid monolayers. Biochim. Biophys. Acta 2004, 1661:212-218.
35. Rybczynska M., Spitaler M., Knebel N.G., Boeck G., Grunicke H., Hofmann J. Effects of miltefosine on various biochemical parameters in a panel of tumor cell lines with different sensitivities. Biochem. Pharmacol. 2001, 62:765-772.
36. Santa-Rita R.M., Henriques-Pons A., Barbosa H.S., de Castro S.L. Effect of the lysophospholipid analogues edelfosine, ilmofosine and miltefosine against Leishmania amazonensis. J. Antimicrob. Chemother. 2004, 54:704-710.
37. Santa-Rita R.M., Santos Barbosa H., Meirelles M.N., de Castro S.L. Effect of the alkyl-lysophospholipids on the proliferation and differentiation of Trypanosoma cruzi. Acta. Trop. 2000, 75:219-228.
38. Seifert K., Duchaene M., Werndorfer W.H. Effects of miltefosine and other alkylphosphocholines on human intestinal parasite Entamoeba histolytica. Antimicrob. Agents Chemother. 2001, 45:1505-1510.
39. Soto J., Toledo J., Gutierrez P., Nicholls R.S., Padilla J., Engel J., Fischer C., Voss A., Berman J. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin. Infect. Dis. 2001, 33:57-61.
40. Stojkovic M., Junghanss T., Krause E., Davidson R.N. Case of typical Old World cutaneous leishmaniasis treatment with miltefosine. Int. J. Dermatol. 2007, 46:385-387.
41. Townson S.M., Boreham P.F., Upcroft P., Upcroft J.A. Resistance to the nitroheterocyclic drugs. Acta Tropica 1994, 56:173-194.
42. Unger C., Damenz W., Fleer E.A., Kim D.J., Breiser A., Hilgard P., Engel J., Nagel G., Eibl H. Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo. Acta Oncol. 1989, 28:213-217.
43. Überall F., Oberhuber H., Maly K., Zaknun J., Demuth L., Grunicke H.H. Hexadecylphosphocholine inhibits inositol phosphate formation and protein kinase C activity. Cancer Res. 1991, 51:807-812.
44. Upcroft J.A., Campbell R.W., Benakli K., Upcroft P., Vanelle P. Efficacy of new 5-nitroimidazoles against metronidazole-susceptible and resistant Giardia, Trichomonas, and Entamoeba spp. Antimicrob. Agents Chemother. 1999, 43:73-77.
45. Walochnik J., Obwaller A., Gruber F., Mildner M., Tschachler E., Suchomel M., Duchene M., Auer H. Anti-acanthamoeba efficacy and toxicity of miltefosine in an organotypic skin equivalent. J. Antimicrob. Chemother. 2009, 64:539-545.
46. Widmer F., Wright L.C., Obando D., Handke R., Ganendren R., Ellis D.H., Sorrell T.C. Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis. Antimicrob. Agents Chemother. 2006, 50(2):414-421.
47. Wieder T., Reutter W., Orfanos C.E., Geilen C.C. Mechanisms of action of phospholipid analogs as anticancer compounds. Prog. Lipid. Res. 1999, 38:249-259.
48. World Health Organization (WHO), 1998. The World Health Report. Life in the 21st Century: Vision for all. 2. Measuring Health. World Health Organization, Geneva, Switzerland, pp. 39-60.
49. Youssef M.Y.M., Eissa M.M., Sadaka H.A.H., Eissa M.M., Rizk A.M. Effect of ivermectin on combined intestinal protozoal infection (giardiases and cryptosporidiosis). J. Egypt. Soc. Parasitol. 1996, 26:543-553.